Format

Send to

Choose Destination
Cancer Cell. 2015 May 11;27(5):607-9. doi: 10.1016/j.ccell.2015.04.016.

Charting the "Splice" Routes to MDS.

Author information

1
Division of Hematology, Brigham and Women's Hospital, Boston, MA 02115, USA; Dana-Farber Cancer Institute, Boston, MA 02115, USA; Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115, USA.
2
Division of Hematology, Brigham and Women's Hospital, Boston, MA 02115, USA; Dana-Farber Cancer Institute, Boston, MA 02115, USA. Electronic address: bebert@partners.org.

Abstract

Mutations in components of the 3' mRNA splicing machinery are found in almost 50% of myelodysplastic syndrome (MDS) cases. In this issue of Cancer Cell, Kim and colleagues, Colla and colleagues, and Shirai and colleagues report on the impact of mutated or dysregulated splicing factors to hematopoiesis, mRNA splicing, and MDS pathogenesis.

PMID:
25965565
DOI:
10.1016/j.ccell.2015.04.016
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center